课题基金 / 基金详情

Development of Novel Therapeutics for Postsurgical Pain

Development of Novel Therapeutics for Postsurgical Pain
术后疼痛新疗法的开发
批准号:
6622254
负责人:
KENNETH W NARDUCY
金额:
$39.98万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1998
资助国家:
美国
项目状态:
已结题
起止时间:
1998-11-01 至 2004-02-29

项目摘要

项目成果

KENNETH W NARDUCY的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Acetaminophen and NSAIDs have been used routinely for treatment of pain and/or fever. This dual action is sometimes contraindicated. In many instances, pain needs to be controlled without masking symptomatic fever (e.g., during the postoperative period). These drugs can cause hepatotoxicity, particularly after ingestion of large doses or from chronic use (especially when liver function has been compromised), which can lead to death. We are exploring a series of new and proprietary derivatives of acetaminophen that have good pharmacological potency and little hepatotoxic, nephrotoxic, or antipyretic effects. In preliminary studies, the initial compounds demonstrated high analgesic activity free from antipyretic activity and hepatotoxicity. In Phase I, we further characterized these initial compounds and several other analogs/derivatives and identified a lead candidate drug. We will further test and develop this drug in Phase II for treating postoperative pain and for other analgesic treatments where acetaminophen is contraindicated. We will also use a combination of in vitro and in vivo models to evaluate additional analogs and derivatives of the Phase I lead candidate drug. We will choose second-generation candidates based on efficacy, pharmacokinetic, and toxicity evaluations. PROPOSED COMMERCIAL APPLICATION: The market for pain relievers in the US is estimated to be approaching $6 billion. Acetaminophen (marketed under the name Tylenol(TM) and other brand names) represents about 48% of that market. Although widely used, acetaminophen is not without some serious side effects. There is a clear unmet medical need for pain relievers that are effective but have a better safety profile than acetaminophen. This research is directed at developing a pain reliever that is as effective as acetaminophen but with fewer side effects. This drug would be targeted at those patients most at risk from acetaminophen toxicity, particularly those who must take pain relievers on a chronic basis, and those with postoperative pain where masking of fever by acetaminophen could delay the diagnosis of infection.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Development of Non-Narcotic Intravenous Analgesics
  • 批准号:
    7161522
  • 项目类别:
  • 资助金额:
    $11.19万
  • 财政年份:
    2007
  • 负责人:
    KENNETH W NARDUCY
  • 依托单位:
Novel drug combinations for the management of pain
  • 批准号:
    7054738
  • 项目类别:
  • 资助金额:
    $53.57万
  • 财政年份:
    2003
  • 负责人:
    KENNETH W NARDUCY
  • 依托单位:
Development of SCP-1/opioid combinations for pain
  • 批准号:
    6582854
  • 项目类别:
  • 资助金额:
    $9.99万
  • 财政年份:
    2003
  • 负责人:
    KENNETH W NARDUCY
  • 依托单位:
ANALGESICS FOR CHRONIC PAIN TREATMENT IN THE ELDERLY
  • 批准号:
    6298399
  • 项目类别:
  • 资助金额:
    $10.0万
  • 财政年份:
    2001
  • 负责人:
    KENNETH W NARDUCY
  • 依托单位:
海外基金